Isr Med Assoc J
-
Comparative Study
Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data.
There is a lack of real-life clinical data for biosimilar etanercept, an anti-TNF blocking fusion protein. We describe the comparable efficacy and safety of originator and biosimilar etanercept in rheumatoid arthritis (RA) patients in a real-life clinical setting. Our data confirm that a biosimilar etanercept can be safely used as first-line treatment as well as in patients switched from a previous originator compound. ⋯ The efficacy and safety profiles of originator and biosimilar etanercept are comparable in RA patients in a real-life clinical setting. Further studies are needed to confirm these preliminary findings.
-
Multicenter Study
Apixaban in Patients with Atrial Fibrillation and Severe Renal Dysfunction: Findings from a National Registry.
Real-world information regarding the use of direct oral anticoagulants therapy and the outcome in patients with renal dysfunction is limited. ⋯ Apixaban might be a reasonable alternative to warfarin in patients with severe renal impairment.